PMID- 20334696 OWN - NLM STAT- MEDLINE DCOM- 20101124 LR - 20211020 IS - 1476-511X (Electronic) IS - 1476-511X (Linking) VI - 9 DP - 2010 Mar 25 TI - Methodological constraints in interpreting serum paraoxonase-1 activity measurements: an example from a study in HIV-infected patients. PG - 32 LID - 10.1186/1476-511X-9-32 [doi] AB - BACKGROUND: Paraoxonase-1 (PON1) is an antioxidant enzyme that attenuates the production of the monocyte chemoattractant protein-1 (MCP-1) in vitro. Although oxidation and inflammation are closely related processes, the association between PON1 and MCP-1 has not been completely characterised due, probably, to that the current use of synthetic substrates for PON1 measurement limits the interpretation of the data. In the present study, we explored the relationships between the circulating levels of PON1 and MCP-1 in human immunodeficiency virus-infected patients in relation to the multifunctional capabilities of PON1. METHODS: We measured selected variables in 227 patients and in a control group of 409 participants. Serum PON1 esterase and lactonase activities were measured as the rates of hydrolysis of paraoxon and of 5-(thiobutyl)-butyrolactone, respectively. Oxidised LDL and MCP-1 concentrations were determined by enzyme-linked immunosorbent assay. High-density lipoproteins cholesterol, apolipoprotein A-I, and C-reactive protein concentrations were measured by standard automated methods. RESULTS: There were significant relationships between PON1 activity and several indices of oxidation and inflammation in control subjects and in infected patients. However, these relationships varied not only with disease status but also on the type of substrate used for PON1 measurement. CONCLUSION: The present study is a cautionary tale highlighting that results of clinical studies on PON1 may vary depending on the methods used as well as the disease studied. Until more specific methods using physiologically-akin substrates are developed for PON1 measurement, we suggest the simultaneous employment of at least two different substrates in order to improve the reliability of the results obtained. FAU - Parra, Sandra AU - Parra S AD - Centre de Recerca Biomedica, Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Reus, Catalunya, Spain. FAU - Marsillach, Judit AU - Marsillach J FAU - Aragones, Gerard AU - Aragones G FAU - Rull, Anna AU - Rull A FAU - Beltran-Debon, Raul AU - Beltran-Debon R FAU - Alonso-Villaverde, Carlos AU - Alonso-Villaverde C FAU - Joven, Jorge AU - Joven J FAU - Camps, Jordi AU - Camps J LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20100325 PL - England TA - Lipids Health Dis JT - Lipids in health and disease JID - 101147696 RN - 0 (Apolipoprotein A-I) RN - 0 (CCL2 protein, human) RN - 0 (Chemokine CCL2) RN - 0 (Cholesterol, HDL) RN - 0 (Lactones) RN - 9007-41-4 (C-Reactive Protein) RN - EC 3.1.8.1 (Aryldialkylphosphatase) RN - EC 3.1.8.1 (PON1 protein, human) RN - Q9CX8P80JW (Paraoxon) RN - S88TT14065 (Oxygen) SB - IM MH - Apolipoprotein A-I/biosynthesis MH - Aryldialkylphosphatase/*blood MH - C-Reactive Protein/biosynthesis MH - Chemokine CCL2/blood MH - Cholesterol, HDL/metabolism MH - Clinical Laboratory Techniques MH - Enzyme-Linked Immunosorbent Assay/methods MH - HIV Infections/*blood MH - Humans MH - Inflammation MH - Lactones/blood MH - Oxygen/chemistry MH - Paraoxon/blood MH - *Research Design PMC - PMC2852375 EDAT- 2010/03/26 06:00 MHDA- 2010/12/14 06:00 PMCR- 2010/03/25 CRDT- 2010/03/26 06:00 PHST- 2010/02/24 00:00 [received] PHST- 2010/03/25 00:00 [accepted] PHST- 2010/03/26 06:00 [entrez] PHST- 2010/03/26 06:00 [pubmed] PHST- 2010/12/14 06:00 [medline] PHST- 2010/03/25 00:00 [pmc-release] AID - 1476-511X-9-32 [pii] AID - 10.1186/1476-511X-9-32 [doi] PST - epublish SO - Lipids Health Dis. 2010 Mar 25;9:32. doi: 10.1186/1476-511X-9-32.